Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Total Valuation
Cytosorbents has a market cap or net worth of $56.35M. The enterprise value is $78.15M.
Market Cap$56.35M
Enterprise Value$78.15M
Share Statistics
Cytosorbents has 62,610,374 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,610,374
Owned by Insiders4.99%
Owned by Institutions16.62%
Financial Efficiency
Cytosorbents’s return on equity (ROE) is -1.87 and return on invested capital (ROIC) is -40.84%.
Return on Equity (ROE)-1.87
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-40.84%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee238.89K
Profits Per Employee-139.05K
Employee Count149
Asset Turnover0.75
Inventory Turnover3.83
Valuation Ratios
The current PE Ratio of Cytosorbents is -2.39. Cytosorbents’s PEG ratio is 0.41.
PE Ratio-2.39
PS Ratio0.00
PB Ratio4.29
Price to Fair Value4.46
Price to FCF-3.61
Price to Operating Cash Flow-3.30
PEG Ratio0.41
Income Statement
In the last 12 months, Cytosorbents had revenue of 35.59M and earned -20.72M in profits. Earnings per share was -0.38.
Revenue35.59M
Gross Profit25.13M
Operating Income-16.79M
Pretax Income-22.41M
Net Income-20.72M
EBITDA-19.26M
Earnings Per Share (EPS)-0.38
Cash Flow
In the last 12 months, operating cash flow was -14.43M and capital expenditures -669.43K, giving a free cash flow of -15.10M billion.
Operating Cash Flow-14.43M
Free Cash Flow-15.10M
Free Cash Flow per Share-0.24
Dividends & Yields
Cytosorbents pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change-13.27%
50-Day Moving Average1.00
200-Day Moving Average1.03
Relative Strength Index (RSI)38.76
Average Volume (3m)124.97K
Important Dates
Cytosorbents upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend Date―
Financial Position
Cytosorbents as a current ratio of 2.20, with Debt / Equity ratio of 242.13%
Current Ratio2.20
Quick Ratio1.92
Debt to Market Cap0.29
Net Debt to EBITDA-1.23
Interest Coverage Ratio-12.00
Taxes
In the past 12 months, Cytosorbents has paid -1.69M in taxes.
Income Tax-1.69M
Effective Tax Rate0.08
Enterprise Valuation
Cytosorbents EV to EBITDA ratio is -3.80, with an EV/FCF ratio of -4.97.
EV to Sales2.06
EV to EBITDA-3.80
EV to Free Cash Flow-4.97
EV to Operating Cash Flow-5.07
Balance Sheet
Cytosorbents has $3.28M in cash and marketable securities with $26.89M in debt, giving a net cash position of $23.61M billion.
Cash & Marketable Securities$3.28M
Total Debt$26.89M
Net Cash$23.61M
Net Cash Per Share$0.38
Tangible Book Value Per Share$0.14
Margins
Gross margin is 72.04%, with operating margin of -47.16%, and net profit margin of -58.21%.
Gross Margin72.04%
Operating Margin-47.16%
Pretax Margin-62.96%
Net Profit Margin-58.21%
EBITDA Margin-54.11%
EBIT Margin-59.03%
Analyst Forecast
The average price target for Cytosorbents is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.00
Price Target Upside17.65% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-5.86%
EPS Growth Forecast50.76%